RACHEL NEAL: Open Payments
NPI 1811401318 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,001 in 53 payments from 11 companies in 2025. Trend: 2023 $48 · 2024 $203 · 2025 $1,001
Food & beverage: $1,001
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $284 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $266 |
| Lilly USA, LLC | 14 | $195 |
| Novo Nordisk Inc | 3 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $47 |
| ABBVIE INC. | 2 | $36 |
| PFIZER INC. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 3 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Abbott Laboratories | 1 | $22 |
Products named: Kerendia, AIRSUPRA, MOUNJARO, FARXIGA, Ozempic, ZENPEP, UBRELVY, BREZTRI.
Industry payments across AR — which companies pay providers there.
